Artesunate

(Artesunate®)

Artesunate

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (intravenous; 110 mg in a single-dose vial)
Drug ClassAntimalarials
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Artesunate is indicated for the initial treatment of severe malaria in both adults and children, showing high efficacy in reducing symptoms and parasite load. However, it requires a follow-up with an appropriate oral antimalarial regimen to complete the treatment effectively.
  • Nine studies provided insights into Artesunate's safety and effectiveness compared to other antimalarials.
  • Comparisons between combinations such as Artesunate + Sulfadoxine-Pyrimethamine (AS+SP) suggest evolving efficacy that requires continuous surveillance and potential adjustments to malaria treatment strategies.
  • In comparison with other Artemisinin Combination Therapies (ACTs), Pyronaridine-Artesunate may have equal or superior efficacy but carries an increased risk of mild drug-induced liver injury, indicating a specific safety consideration against its effectiveness.
  • The combination of Artesunate and Primaquine for the radical cure of vivax malaria was found safe; however, concerns revolve around haemolysis due to Primaquine primarily in patients with G6PD deficiency rather than direct issues associated with Artesunate itself.
  • For Seasonal Malaria Chemoprevention (SMC), especially among children under 5 years old extending to those ≤15 years old in areas experiencing high transmission rates, preventive strategies involving Artesunate could significantly benefit.

Product Monograph / Prescribing Information

Document TitleYearSource
Artesunate (Artesunate) Prescribing Information.2021Amivas LLC., Wilmington Delaware

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Meta-analysis on Plasmodium falciparum sulfadoxine-pyrimethamine resistance-conferring mutations in India identifies hot spots for genetic surveillance.2024International Journal of Antimicrobial Agents
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.2024The Lancet. Infectious Diseases
Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.2024The Lancet. Infectious Diseases
Systematic review and meta-analysis of seasonal malaria chemoprevention.2024The American Journal of Tropical Medicine and Hygiene
Artesunate-mefloquine therapy for uncomplicated Plasmodium falciparum malaria: an updated systematic review and meta-analysis of efficacy and safety.2024Transactions of The Royal Society of Tropical Medicine and Hygiene
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria.2022Cochrane Database of Systematic Reviews
Intermittent preventive treatment for malaria in infants.2021Cochrane Database of Systematic Reviews
Safety and efficacy of adjunctive therapy with artesunate in the treatment of severe malaria: a systematic review and meta-analysis.2020Frontiers in Pharmacology
Systematic review of artesunate pharmacokinetics: Implication for treatment of resistant malaria. 2019International Journal of Infectious Diseases

Clinical Practice Guidelines

Document TitleYearSource
KDIGO 2021 clinical practice guideline for the management of glomerular diseases.2021Official Journal of the International Society of Nephrology